Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said. The Phase 2 study, which involved women with the most common form of breast cancer, found that those treated with hormone drug letrozole plus Pfizer's palbociclib lived for an average of 20.2 months before their cancer progressed, compared with 10.2 months for patients given letrozole alone. Pfizer is still discussing a regulatory pathway for the drug and has not decided whether to seek accelerated approval based on Phase 2 trial results, said Mace Rothenberg, chief medical officer for Pfizer's oncology unit. The trial tested the pill, which targets proteins involved in cell division, in post-menopausal women with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment